VolitionRx Announces Collaboration with Sysmex
Rhea-AI Summary
VolitionRx (NYSE American: VNRX) announced a collaboration with Sysmex (TYO: 6869) to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex diagnostic platform. The partnership supports Volition's strategy to out-license its NETs test globally and target diseases associated with NETosis, including sepsis.
According to Volition, the Nu.Q NETs test aims to aid clinical decision-making, support personalized care, and offer low-cost monitoring of patient condition. The company cites a $3.8 billion Total Addressable Market for the Nu.Q NETs assay.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – VNRX
On the day this news was published, VNRX declined 2.14%, reflecting a moderate negative market reaction. Argus tracked a peak move of +3.7% during that session. Argus tracked a trough of -17.3% from its starting point during tracking. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $375K from the company's valuation, bringing the market cap to $17.15M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Peers on Argus
Sector peers show mixed moves with declines in ICCM (-2.74%), LUNG (-3.85%) and APYX (-8.7%), while TELA (+12.18%) and CTSO (+5.9%) trade higher, suggesting stock-specific factors rather than a unified sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jun 07 | Equity offering | Negative | -20.4% | Dilutive public offering of shares and warrants priced at $1.55. |
| Jun 03 | IP / patent news | Positive | -10.3% | New patent filing protecting Nu.Q® NETs test for Ebola triage use. |
| May 27 | Commercial update | Positive | +0.0% | Highlight of Q1 revenue growth and large multi-billion-dollar TAMs. |
| May 14 | Earnings update | Neutral | -9.1% | Q1 2026 financials with higher revenue but continued losses and cash burn. |
| May 11 | Conference call notice | Neutral | -8.9% | Scheduling of earnings and business update conference call. |
Recent news, including offerings and patent/commercial updates, has often been followed by flat or negative price reactions, even on seemingly positive developments.
Over the last few months, VolitionRx has balanced financing needs with commercial and clinical progress. A $4.6 million public offering and use of warrants followed earlier disclosures of Q1 2026 revenue near $1.0 million and growing Nu.Q® NETs and Vet programs. Patent protection and commercial momentum across multi-billion-dollar TAMs have not consistently translated into positive next-day price moves. Today’s Sysmex collaboration extends the Nu.Q® NETs partnership theme within this financing-heavy backdrop.
Regulatory & Risk Context
An effective Form S-3 shelf dated 2026-02-09 registers 17,968,090 common shares for resale by existing investors, primarily holders of convertible notes and warrants such as Lind Global Asset Management. The company receives no proceeds from these resale transactions, but the registered block can create share overhang if large amounts are sold into the market.
Market Pulse Summary
This announcement highlights VolitionRx’s collaboration with Sysmex to optimize the Nu.Q® NETs H3.1 assay on a major diagnostics platform, targeting diseases linked to NETosis and a cited $3.8 billion Total Addressable Market. It builds on earlier Nu.Q® NETs and commercial updates while the company continues to manage financing needs through offerings and an effective resale shelf. Investors may watch for concrete commercialization milestones, regulatory progress, and partner-driven adoption metrics from this collaboration.
Key Terms
in vitro diagnostics medical
neutrophil extracellular traps medical
NETosis medical
assay technical
AI-generated analysis. Not financial advice.
Gael Forterre, Chief Commercial Officer, Volition commented:
"We are proud to have entered into this agreement with Sysmex, as we implement our strategy to out license our proprietary Nu.Q® NETs test to large companies with a worldwide presence, to leverage their knowledge of specific diseases, product development, regulatory experience and their installed base of proprietary analyzers. Sysmex is a global leader in the field of in vitro diagnostics for hemostasis and thrombosis, among other diseases, where Neutrophil Extracellular Traps ("NETS") play such an important role.
"Following the successful transfer of our Nu.Q® NETs assay onto Sysmex's platform we are delighted to commence the optimization phase in diseases associated with NETosis. NETosis is implicated in a wide range of diseases, including sepsis and other acute and chronic diseases.
"We believe that Volition's Nu.Q® NETs test could provide not only improved diagnostic information to aid clinical decision-making and personalized care, but could also be a low-cost test to continue to monitor a patient's condition.
"The commercial opportunity for the Nu.Q® NETs assay is significant, with a Total Addressable Market of
"It is exciting to progress the collaboration with Sysmex and we look forward to a fruitful long-term partnership together."
[1] Data on File, Volition TAM Model
About Sysmex
Sysmex Corporation, headquartered in
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London.
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nu.Q®, Nucleosomics™, Capture-PCR™, Capture-Seq™ and rNuQ™and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.
View original content:https://www.prnewswire.com/news-releases/volitionrx-announces-collaboration-with-sysmex-302803026.html
SOURCE VolitionRx Limited